|
|
||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Department of Surgery, Maastricht University, Maastricht, Netherlands (MJB, PBS, and NEPD), and the Department of Anatomy and Embryology, University of Amsterdam (WHL).
2 Supported by grant 902-23-098 from the Netherlands Organization for Scientific Research. 3 Address reprint requests to NEP Deutz, Department of Surgery, Fac II, Maastricht University, PO Box 616, 6200 MD Maastricht, Netherlands. E-mail: nep.deutz{at}ah.unimaas.nl.
| ABSTRACT |
|---|
|
|
|---|
Objective: Because the effect of L-arginine administration on the protein metabolism of different organs is unknown, the aim of the study was to elucidate the effects of exogenous supplementation of L-arginine during endotoxemia on the in vivo protein metabolism of individual organs and at the whole-body level.
Design: Female pigs were cannulated with catheters in the aorta and the splenic, caval, portal, hepatic, and renal veins, enabling measurements across the hindquarter, portal-drained viscera, liver, and kidneys. Endotoxemia was induced by a 24-h continuous intravenous infusion of endotoxin (3 µg·kg body wt-1·h-1). At 8 h, an intravenous infusion of L-arginine was started (n = 8). Control pigs (n = 6) received L-alanine. At 24 h, blood was sampled. After cessation of the endotoxin infusion, L-arginine and L-alanine infusions were continued as a supplement in the enterally infused diet. At 48 h, blood samples were obtained during the postendotoxemic and nutritionally supported conditions. Stable isotopes were used to assess protein metabolism and phenylalanine hydroxylation.
Results: Both during and after the endotoxin challenge, L-arginine administration enhanced protein synthesis and degradation across the hindquarter and simultaneously reduced protein synthesis and degradation in the liver at equal rates. Protein turnover across the kidneys and portal-drained viscera remained unaffected. After endotoxemia, L-arginine infusion decreased whole-body protein turnover without affecting the net protein balance.
Conclusion: L-Arginine administration affects protein turnover of the muscle area and the liver oppositely.
Key Words: Arginine supplementation enteral nutrition endotoxin sepsis disease model intestine gut liver muscle kidney stable isotopes protein metabolism acute phase protein phenylalanine hydroxylation pigs
| INTRODUCTION |
|---|
|
|
|---|
Results of clinical studies using L-argininesupplemented dietary formulas suggest a significant benefit for injured patients, not only through improved immune function but also through improved nitrogen balance (1416). However, because these formulas contain many different supplements, it is not possible to discriminate the effect of L-arginine as an individual component.
It remains to be elucidated whether L-arginine supplementation in critical illness can modify protein metabolism; therefore, we assessed the effect of L-arginine supplementation on protein metabolism in the hindquarter, portal-drained viscera, liver, and kidney in this model of endotoxemia.
Because, in general, endotoxin is slowly released from the gut (17) and only low doses of endotoxin are detected in the circulation (18) in humans with sepsis, we infused a low dose of endotoxin for several hours in pigs. We hypothesized that exogenous L-arginine administration during the initial phase of sepsis could induce an excessive production of nitric oxide. Therefore, L-arginine was started a few hours after initiation of the endotoxin infusion to prevent nitric oxidemediated hypotension and shock.
The aim of the study was to investigate the effects of intravenously administered L-arginine during endotoxemia and of intragastrically administered L-arginine after endotoxemia on protein metabolism. The use of stable isotopes in a multicatheterized animal model enabled us to investigate the changes in protein synthesis and breakdown at the whole-body level and in individual organs. To our knowledge, the influence of L-arginine treatment during or after endotoxemia on protein metabolism in individual organisms has not been studied.
| MATERIALS AND METHODS |
|---|
|
|
|---|
300 g/d. Before surgery, pigs were randomly assigned to 1 of 2 treatment groups. The Animal Ethics Committee of Maastricht University approved the study.
Surgical procedure
The night before surgery, the pigs were not allowed food. One hour after the pigs were premedicated with 10 mg azoperone/kg body wt (Stresnil; Janssen Pharmaceutica, Beersse, Belgium) intramuscularly, anesthesia was induced with a mixture of nitrous oxide:oxygen (1:2, by vol) and halothane (0.8%). After intubation, the pigs were intravenously administrated 6.25 mg Lincomycin· 2 HCl/kg body wt (AUV, Cuyk, Netherlands) as a bactericidal prophylactic and 12.5 mg Spectinomycin·HCl lyophil/kg body wt (AUV) as a bacteriostatic prophylactic. Fluxinine (50 mg/kg body wt, Finadyne; Schering-Ploegh, Brussels, Belgium) was given to prevent coagulation and as a postoperative analgesic. During surgery, anesthesia was maintained with a mixture of nitrous oxide:oxygen and halothane and with intravenous Lactetrol (5.76 g NaCl/L, 0.37 g KCl/L, 0.37 g CaCl2/L, 0.2 g MgCl2/L, 5 g sodium lactate/L, and methyl p-hydroxybenzoic acid/L; Janssen Pharmaceutica). The surgical procedure was described in detail previously (19, 20). In brief, 8 vessels were cannulated after a midline incision was made. Two catheters were inserted in the abdominal aorta; one just above the bifurcation (A1) and one above the right renal vein (A2). Two catheters were inserted in the inferior caval vein (V1 and V2 catheters). Furthermore, catheters were inserted in the portal, hepatic, splenic, and renal veins. The abdominal aorta and the splenic vein catheters were used for the infusion of p-aminohippuric acid (PAH) to measure plasma flow, and the V2 catheter was used for the infusion of isotopes and endotoxin. Blood collected from the abdominal aorta (A2) in combination with the portal vein, hepatic vein, V1, and renal vein catheters was used to measure amino acid flux in the portal-drained viscera, liver, hindquarter, and kidney, respectively. In addition, a gastrostomy catheter was inserted in the stomach to enable infusion of a liquid diet. All catheters were tunneled through the abdominal wall and skin.
The pigs wore a canvas harness to protect the catheters and the stoma and to allow easy handling. Postoperatively, the pigs were fed 100 g on day 1, 200 g on day 2, and 1 kg on day 3 and thereafter. To prevent infections and to maintain patency, the catheters were regularly flushed with a mixture of saline (150 mmol/L), gentamycin sulfate (20 g/L, 5%; AUV), and chymotrypsin (0.225 U/L; Merck, Darmstadt, Germany).
Postoperative care
The postoperative care was standard (19, 20). The pigs were placed in a movable cage to get accustomed to their experimental condition. The postoperative care procedures were standard (19, 20). During the recovery (1015 d) and experimental (7 d) periods, the animals remained healthy and had no signs of infection. Four weeks after the operation, the position of the catheter tips was checked under anesthesia with fluoroscopy.
Experimental protocol
From the tenth postoperative day onward, a ready-to-use liquid diet with an osmolarity of 255 mOsmol/L (63 g casein protein/L, 141 g carbohydrate/L, 11 g sugar/L, 128 g polysaccharides/L, 49 g fat/L, and unspecified amounts of minerals, trace elements, and vitamins; Nutrison Steriflo Protein-Plus; Nutricia, Zoetermeer, Netherlands) was intragastrically infused into the gastrostomy catheter via a swivel system. This diet is high in protein, has an optimal protein-energy ratio, and contains all the vitamins, minerals, and other nutritional elements to meet the requirements of clinical patients and growing pigs (21). To accustom the pigs to the diet, the pigs received 500 g of their regular diet plus the liquid diet at a rate of 2 mL·kg body wt-1·h-1 on day -3, ie, 10 d postsurgery. On the following 3 d, the diet was infused at a rate of 4 mL·kg body wt-1·h-1 in the absence of the regular diet, corresponding with 0.3 g protein·kg body wt-1·h-1. The experimental design is depicted in Figure 1
.
|
Eight pigs were intravenously infused with L-arginine (isoosmolar rate of 5.3 µmol·kg body wt-1·min-1, pH 7.3), starting 8 h after initiation of the endotoxin infusion (arginine group). Six pigs were infused with alanine (isoenergetic rate of 10.6 µmol·kg body wt-1·min-1, pH 7.3) to correct for the effect of giving an amino acid. The following day (day 1), 24 h after initiation of the endotoxin infusion, blood samples were collected from the arginine group and the control group and then the infusions of endotoxin, saline, and amino acids were stopped. Immediately thereafter, enteral nutrition was restarted (4 mL·kg body wt-1·h-1). The intravenous infusion of L-arginine or L-alanine continued at equal infusion rates through the gastrostomy catheter as a supplement in the enteral meal. The following day (day 2), 24 h after cessation of the endotoxin infusion, blood samples were collected from the arginine group and the control group. The arterial blood pressure, weight, and temperature of the pigs were monitored throughout the experimental period.
Infusion protocol
Background blood samples were taken before the infusions began. On the morning of the trial, 1 h before the endotoxin infusion began, a primed infusion of 25 mmol PAH (A 1422; Sigma Chemical Co) was administered at a rate of
40 mL/h through the splenic vein and abdominal aorta (A1) catheters after an initial bolus of 5 mL (19). Directly after the primed, constant infusion of PAH, a primed, constant infusion of the stable isotopes L-[ring-2H5] phenylalanine ([D5]phenylalanine; prime: 1 µmol/kg body wt; infusion: 1.9 µmol·kg body wt-1·h-1), L-[ring-3,5-2H2] tyrosine ([D2] tyrosine; prime: 1 µmol/kg body wt; infusion: 1.9 µmol·kg body wt-1·h-1), and L-[1-13C]valine ([13C]valine; prime: 5.3 µmol/kg body wt; infusion: 5.3 µmol·kg body wt-1·h-1) was started via the V2 catheter. In addition, a primed, constant infusion of L-[guanidino-15N2]arginine, L-[ureido-13C; 5,5-2H2]citrulline, and [13C] urea was administered for the purpose of measuring nitric oxide metabolism, the results of which will be reported elsewhere. Stable isotopes were purchased from Mass Trace, Woburn, MA. During the last 60 min of the infusion protocol, an isotopic plateau (the calculated slope of isotopic enrichment against time not different from zero) was observed (22). One hour after the start of the primed infusion of PAH, steady state conditions for PAH (data not shown) were obtained. Blood samples were collected in triplicate at 15-min intervals, during the last 60 min of the infusion of PAH and the isotopes.
Sample processing
Immediately after the blood samples were collected, the blood was distributed into heparin-containing tubes (Sarstedt, Nümbrecht, Germany) on ice. For the analysis of blood gases (arterial pH, HCO3- , arterial pressure of oxygen and carbon dioxide, and standard pressure of oxygen), 0.2 mL blood was sealed in 1-mL airtight heparin-containing syringes and immediately analyzed with an automatic blood gas system (Acid Base Laboratory, Radiometer, Copenhagen). Hematocrit was obtained with a microfuge. For the measurement of PAH concentrations, 300 µL whole blood was added to 600 µL of 120 g trichloroacetic acid solution/L; the solution was thoroughly mixed and centrifuged (4°C, 5 min, 8500 x g) followed by the collection of supernatant fluid and plasma. The plasma was kept on ice until used. For the amino acid analysis, 500 µL plasma was deproteinized by mixing it with 20 mg dry sulfosalicylic acid. All samples were stored at -80°C until analyzed.
Biochemical analysis
PAH was detected spectrophotometrically after deacetylation of the supernatant fluid at 100°C for 45 min (23). The plasma concentrations of amino acids were measured with a fully automated HPLC system (Pharmacia, Woerden, Netherlands) after precolumn derivatization with o-phthaldialdehyde (24). The enrichments of amino acids were calculated as the tracer-tracee ratios (TTRs) and were calculated with a fully automated online liquid chromatographymass spectrometry (LC-MS; Thermoquest LCQ, Veenendaal, Netherlands) system connected to an HPLC system (22).
Concentrations of the acute phase proteins haptoglobin, fibrinogen, and
1-antitrypsin and of total protein in plasma were measured with a nephelometer (model BN 100; Dade-Behring Vertriebs GmbH and Co, Schwalbach, Germany). Proteins were determined by using antihuman haptoglobin, fibrinogen, and
1-antitrypsin antibodies from rabbits (Dade-Behring) in the same way as human plasma samples. Standard curves for haptoglobin and fibrinogen were constructed by using a purified human (Dade-Behring) and a secondary porcine standard (Sigma Chemical Co). High correlation coefficients (>0.9) were found for the 2 proteins between the standards. Because a porcine standard for fibrinogen was not available, protein concentrations were expressed in human units.
Calculations
The total of amino acids represents the sum of measurable
-amino acids (glutamine, glycine, threonine, histidine, citrulline, alanine, taurine, arginine,
-amino butyric acid, tyrosine, valine, methionine, isoleucine, phenylalanine, tryptophan, leucine, ornithine, and lysine) and the total branched-chain amino acids (BCAAs) represents the sum of valine, leucine, and isoleucine.
Organ phenylalanine and valine kinetics
The portal-drained viscera are defined as the total of all portal-drained organs, mainly the intestines. The splanchnic area includes the portal-drained viscera and liver; therefore, calculations for the liver were made by subtracting values for the portal-drained viscera from those for the splanchnic area. Substrate metabolism across the hindquarter, the portal-drained viscera, the liver, and the kidneys was calculated in a 2-compartment model as described previously (25). The plasma flow rates (mL·kg body wt-1·min-1) across the organs were calculated as follows:
![]() | (1) |
![]() | (2) |
Substrate net balance (NB; in nmol·kg body wt-1·min-1) was calculated as shown below:
![]() | (3) |
The NB of the tracer (nmol·kg body wt-1·min-1) was calculated similarly, but corrected for the background (pretracer infusion) TTR values:
![]() | (4) |
The disposal rate (nmol·kg body wt-1·min-1) is the total rate of metabolism of the amino acid (incorporation into protein plus degradation) and was calculated as follows:
![]() | (5) |
The TTRV was thought to approach best the intracellular enrichment (precursor pool) of the organ (26). Because the NB of an amino acid across an organ is the net difference between production and disposal, the production is represented as
![]() | (6) |
In the muscle, gut, and kidneys, the disposal and production of phenylalanine are a reflection of protein synthesis and protein breakdown, respectively, because these organs have relatively low phenylalanine 4-monooxygenase activity (27). Valine disposed in these organs can either become transaminated or be used in protein synthesis (28). In the liver, valine is mainly used for protein synthesis because the valine degradation rate is considered to be low (28, 29). Disposal of phenylalanine by the liver is a combination of protein synthesis and hydroxylation of phenylalanine to tyrosine (27). To calculate the rate of phenylalanine hydroxylation in an organ, the conversion rate of [D5]phenylalanine to [D4]tyrosine (Phe
Tyr) was calculated by using Equations 710![]()
![]()
![]()
. The arterial [D5]phenylalanine TTR was thought to best reflect the precursor pool. Because of the eventual loss of tyrosine across the organ by fractional extraction, the NB of [D4]tyrosine (NB[D4]Tyr) was corrected. This fractional extraction of tyrosine (FE[D4]Tyr) was estimated by using NB[D2]Tyr as calculated in Equation 7
. NB[D4]Tyr, as calculated in Equation 8
, was used to calculate Phe
Tyr (Equation 9
).
![]() | (7) |
![]() | (8) |
![]() | (9) |
Across the portal-drained viscera, the total production rate of a substrate is the combination of the substrate derived from endogenous production plus the output of the substrate absorbed by the gut from the enterally infused meal that is not retained for disposal and escapes metabolism. The total production rate of a substrate can be corrected for the contribution of the substrate derived from nondisposed absorption. This gives a good approximate of the part of the substrate produced that represents endogenous production in the portal-drained viscera.
Whole-body phenylalanine and valine kinetics
The whole-body rate of appearance (RA; in nmol·kg bw-1 ·min-1) of phenylalanine, valine, or tyrosine was derived as follows:
![]() | (10) |
The whole-body RA of phenylalanine was used as an indication of whole-body protein breakdown because this amino acid cannot be newly synthesized. The rate of whole-body phenylalanine hydroxylation was calculated accounting for the conversion of [D5]phenylalanine to [D4]tyrosine:
![]() | (11) |
Tyr:
![]() |
Statistics
The results are presented as means ± SEMs. If the normality or equal variance test failed, data were transformed or log transformed where appropriate. The data were analyzed with a two-factor repeated-measures analysis of variance, with time (days 1, 0, 1, and 2) as a within-subject factor and treatment (arginine or alanine) as a between-subject factor. The level of significance was set at P < 0.05, and P values are given for the time effect, the group effect, and the time x group interaction. When an overall significance for time was observed, univariate F tests were used to evaluate contrasts among the different days to assess the immediate effect of endotoxin infusion plus fasting compared with fasting state baseline values (day 1 compared with day 0) and the long-term effect of the endotoxin infusion plus fasting period under fed conditions as compared with fed state baseline values (day 2 compared with day -1). Contrasts between day 0 and day 1 were assessed for the arginine variables in the control group and for the alanine variables within the arginine group after significant time x group interactions were observed. When overall significant time x group interactions were observed, pairwise group comparisons were performed on days 1 and 2 with the use of Bonferroni post hoc tests to adjust the nominal level of significance for the multiple comparisons made (P < 0.05 with correction).
| RESULTS |
|---|
|
|
|---|
|
|
1-antitrypsin and of total protein decreased significantly as a result of the endotoxin infusion during fasting (day 1 compared with day 0 and day 2 compared with day -1) (Table 3
|
|
Tyr were significantly higher than that on day 0, indicating an acceleration of protein breakdown and phenylalanine hydroxylation (Table 5
|
|
|
|
|
Tyr in the liver approximated 10% of the disposal rate of phenylalanine during fasting, both before and after the endotoxin infusion (data not shown). During feeding, phenylalanine hydroxylation was not significantly different from zero because of the relatively low tyrosine enrichment in plasma.
|
|
Tyr across the kidneys was not affected significantly by L-arginine treatment (data not shown). Both during and after endotoxemia, irrespective of L-arginine infusion, Phe
Tyr was
20% of the rate of phenylalanine disposed.
|
|
| DISCUSSION |
|---|
|
|
|---|
The model of endotoxemia used was characterized by increased whole-body and hindquarter protein breakdown, as measured with a stable phenylalanine isotope. In addition, a tyrosine tracer indicated that whole-body phenylalanine hydroxylation simultaneously increased. Supplementation with L-arginine under endotoxemic conditions reduced whole-body protein degradation and protein synthesis, ie, turnover, and decreased the rate of whole-body phenylalanine hydroxylation.
Hindquarter
The net protein breakdown that was observed across the hindquarter within the control group after endotoxin infusion reflects muscle catabolism, one of the main prominent features of the metabolic response to sepsis. Enteral nutrition 1 d after endotoxemia abolished this net protein degradation. The intravenous L-arginine infusion during endotoxemia and intragastric L-arginine infusion 1 d after endotoxemia not only promoted protein synthesis in the hindquarter area but also increased the protein breakdown to a similar extent, therefore not resulting in improved net protein balance. In addition, the efflux of total amino acids by the hindquarter was not affected significantly by the L-arginine infusion, neither during nor after endotoxemia, implying unchanged net protein balance across hindquarter muscle. Enhanced muscle protein synthesis was shown previously in traumatized rats in response to dietary L-arginine; unfortunately, concomitant muscle protein breakdown was not measured in this study (6). High protein turnover is supposed to facilitate a rapid response by means of rapid alteration of enzyme concentrations and elimination of damaged proteins (31). Therefore, although no improved net protein balance was achieved across the muscle by L-arginine infusion, increased muscle protein turnover can be of benefit under altered physiologic conditions such as septicemia.
Portal-drained viscera
Only a few studies of flux in the portal-drained viscera have been conducted because the portal vein is not easily sampled. This study showed that endotoxin infusion during fasting reduced the net catabolism of protein in the portal-drained viscera as a result of protein degradation. Although we detected no changes in phenylalanine disposal, a study of bacteremic rats showed stimulation of intestinal protein synthesis (32), and intravenous L-arginine supplementation decreased protein synthesis in the small intestine of bowel-resected rats (33). In our model of endotoxemia, L-arginine supplementation had no significant effect on the rate of protein synthesis or breakdown in the portal-drained viscera, neither during nor after endotoxemia. Because of the relatively lower protein turnover rate of gut enterocytes in pigs, the eventual effects of L-arginine on protein metabolism in the portal-drained viscera may have become manifest at a later stage of endotoxemia.
Liver
During endotoxemia, cytokine-driven synthesis of acute phase proteins by the liver is activated (34). The observed increase in net liver protein synthesis during and after endotoxin infusion, therefore, appears to represent enhanced synthesis of acute phase proteins. However, the endotoxin-induced protein synthesis was not reflected by an increase in plasma acute phase protein concentrations. Plasma dilution resulting from fluid resuscitation during endotoxin infusion could have concealed possible increases in acute phase protein concentrations. As far as we know, no studies of the effect of L-arginine on hepatic protein metabolism during sepsis or endotoxemia are available. In our in vivo model, L-arginine supplementation during and after endotoxin-infusion exerted a pronounced reducing effect on hepatic protein synthesis and breakdown, ie, protein turnover, without affecting the net balance of protein. Nevertheless, the measured plasma acute phase protein concentrations did not decrease after the L-arginine infusion. Hence, whether the observed decrease in hepatic protein synthesis concerns delayed secretion of secretory proteins or rather concerns structural proteins of endogenous origin remains to be established. The nitric oxide that is generated by the hepatic inducible NOS II enzyme may be involved in the decreased hepatic protein turnover by means of inhibition of cell replication in the liver (35).
Phenylalanine 4-monooxygenase is considered to be predominantly located in the liver (36, 37). Our data indicated a large variability in the hydroxylation of phenylalanine to tyrosine across the liver because of the low enrichment of plasma tyrosine. Phenylalanine hydroxylation in the liver during fasting, irrespective of endotoxin or L-arginine infusion, accounted for
10% of phenylalanine disposal, a finding similar to that of a study performed on human liver in vivo (38).
Kidneys
Dietary intervention with L-arginine has been associated with amelioration of many experimental kidney diseases (39). The effect of L-arginine administration on renal protein synthesis and degradation under septic conditions, however, remains to be explored. In our model of hyperdynamic endotoxemia with well-preserved renal function, the renal synthesis and degradation of protein did not change significantly after treatment with L-arginine, as measured with a phenylalanine isotope. Phenylalanine is not only incorporated into protein because the kidneys of pigs appear to hydroxylate phenylalanine to tyrosine at a rate of 20% of the total phenylalanine disposal rate. This finding is consistent with that of a study in which phenylalanine hydroxylation was found to occur at a rate of 40% in human kidney (38). Neither endotoxemia nor L-arginine exerted any effect on the rate of renal phenylalanine hydroxylation.
During L-arginine supplementation the decline in hepatic protein turnover exceeded the increase in muscle protein turnover, accounting for the decrease in whole-body protein turnover that was observed after endotoxemia. Differences in the severity of the disease and related L-arginine requirements may underlie the way by which L-arginine influences protein metabolism. Because in this sepsis model it was shown that L-arginine infusion increased the whole-body production of nitric oxide (40), the indirect effects of nitric oxide may also be involved in the observed changes in protein metabolism.
On the basis of our results, intravenous or intragastric supplementation with L-arginine appears to be a promising means for increasing protein turnover in the hindquarter muscle after endotoxemia. Although we observed no significant decrease in acute phase protein concentrations, the decrease in protein turnover in the liver after L-arginine infusion under postendotoxemic conditions implies that L-arginine may reduce the severity of the hepatic response to tissue injury and inflammation.
| ACKNOWLEDGMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. C. Luiking and N. E. P. Deutz Biomarkers of Arginine and Lysine Excess J. Nutr., June 1, 2007; 137(6): 1662S - 1668S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. G. van de Poll, G. C. Ligthart-Melis, P. G. Boelens, N. E. P. Deutz, P. A. M. van Leeuwen, and C. H. C. Dejong Intestinal and hepatic metabolism of glutamine and citrulline in humans J. Physiol., June 1, 2007; 581(2): 819 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Stoll and D. G. Burrin Measuring splanchnic amino acid metabolism in vivo using stable isotopic tracers J Anim Sci, April 1, 2006; 84(13_suppl): E60 - E. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. C. Luiking, M. M. Hallemeesch, W. H. Lamers, and N. E. P. Deutz NOS3 is involved in the increased protein and arginine metabolic response in muscle during early endotoxemia in mice Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1258 - E1264. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. L. Vissers, C. H. Dejong, Y. C Luiking, K. C. Fearon, M. F von Meyenfeldt, and N. E. Deutz Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency? Am. J. Clinical Nutrition, May 1, 2005; 81(5): 1142 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. C. Luiking, M. M. Hallemeesch, W. H. Lamers, and N. E. P. Deutz The role of NOS2 and NOS3 in renal protein and arginine metabolism during early endotoxemia in mice Am J Physiol Renal Physiol, April 1, 2005; 288(4): F816 - F822. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. C. Luiking, M. Poeze, G. Ramsay, and N. E. P. Deutz The Role of Arginine in Infection and Sepsis JPEN J Parenter Enteral Nutr, January 1, 2005; 29(1_suppl): S70 - S74. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. C. Luiking, M. M. Hallemeesch, Y.L.J. Vissers, W. H. Lamers, and N.E.P. Deutz In Vivo Whole Body and Organ Arginine Metabolism During Endotoxemia (Sepsis) Is Dependent on Mouse Strain and Gender J. Nutr., October 1, 2004; 134(10): 2768S - 2774S. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. L. J. Vissers, M. M. Hallemeesch, P. B. Soeters, W. H. Lamers, and N. E. P. Deutz NOS2 deficiency increases intestinal metabolism both in nonstimulated and endotoxemic mice Am J Physiol Gastrointest Liver Physiol, May 1, 2004; 286(5): G747 - G751. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. H. van Eijk and N. E. P. Deutz Plasma Protein Synthesis Measurements Using a Proteomics Strategy J. Nutr., June 1, 2003; 133(6): 2084S - 2089. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |